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E-mail address: gislainezilli@hotmail.com (G.Z. RéThe present study was aimed to investigate the behavioral and molecular effects of lamotrigine. To this
aim, Wistar rats were treated with lamotrigine (10 and 20 mg/kg) or imipramine (30 mg/kg) acutely and
chronically. The behavior was assessed using forced swimming test. Brain-derived neurotrophic factor
(BDNF), nerve growth factor (NGF), Proteina Kinase B (PKB, AKT), glycogen synthase kinase 3 (GSK-3)
and B-cell lymphoma 2 (Bcl-2) levels, citrate synthase, creatine kinase and mitochondrial chain (I, II,
II–III and IV) activities were assessed in the brain. The results showed that both treatments reduced
the immobility time. The BDNF were increased in the prefrontal after acute treatment with lamotrigine
(20 mg/kg), and the BDNF and NGF were increased in the prefrontal after chronic treatment with lamo-
trigine in all doses. The AKT increased and Bcl-2 and GSK-3 decreased after both treatments in all brain
areas. The citrate synthase and creatine kinase increased in the amygdala after acute treatment with
imipramine. Chronic treatment with imipramine and lamotrigine (10 mg/kg) increased the creatine
kinase in the hippocampus. The complex I was reduced and the complex II, II–III and IV were increased,
but related with treatment and brain area. In conclusion, lamotrigine exerted antidepressant-like, which
can be attributed to its effects on pathways related to depression, such as neurotrophins, metabolism
energy and signaling cascade.
 2011 Published by Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Depression is a severe disorder that has enormous conse-
quences for the individual’s quality of life, and it is among the most
prevalent forms of mental illness. Clinical symptoms like de-
pressed mood, anhedonia, fatigue or loss of energy, feelings of
worthlessness or guilt, and the diminished ability to concentrate
or think are characteristics of depression. Despite the devastating
impact of depression, relatively little is known about the etiology
and pathogenesis of depression (Larsen et al., 2010).ess under the Elsevier OA license. 
factor; NGF, nerve growth
B; GSK-3, glycogen synthase
us).Lamotrigine is an anticonvulsant drug that has shown efﬁcacy
in the treatment of bipolar depression and resistant major
depressive episodes (Bowden et al., 1999; Calabrese et al., 1999;
Frye et al., 2000; Barbosa et al., 2003). However, the mechanism
of antidepressant action of lamotrigine is still unclear. Although
the blockade of neuronal voltage-dependent sodium channels
elicited by lamotrigine has an important role in its anticonvulsant
effect, and it shares a common action with other mood stabilizing
anticonvulsants, the antiglutamatergic effect of lamotrigine has
been implicated in its mood effect (Ketter et al., 2003). In addition
to these effects, lamotrigine also blocks neuronal voltage-depen-
dent calcium channels (Ketter et al., 2003) Moreover, the reduc-
tion of glutamate release induced by lamotrigine may be related
to the blockade of neuronal voltage-dependent sodium and
calcium channels (Ketter et al., 2003). Reduced glutamatergic
neurotransmission has been related to an antidepressant effect.
For example, antagonists of the N-methyl-D-aspartate (NMDA)
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of depression (Paul and Skolnick, 2003; Réus et al., 2010,
2011). Moreover the lamotrigine presents effects in dopami-
nergic, adrenergic, muscarinic, opioid, adenosine, serotonin
(5HT3) and 5HT1A receptors (for a review see: Goldsmith et al.,
2003).
Evidence indicates that neurotrophins such as brain-derived
neurotrophic factor (BDNF) and nerve growth factor (NGF) may
play a role in the pathophysiology of depression and that antide-
pressants may in part exert their effects through the regulation
of BDNF and NGF. Several clinical studies have reported that serum
BDNF levels are decreased in depressed patients, and that they can
be normalized by antidepressant treatment (Brunoni et al., 2008;
Gervasoni et al., 2005).
The understanding of the signaling pathways in neurons or the
investigation of new components with already discovered ones can
be considered as the basis to ﬁnding molecular–biological causes
of neuropsychiatric diseases (D’Sa and Duman, 2002). Protein
Kinase B (PKB, AKT), glycogen synthase kinase 3 (GSK-3) and com-
ponents regulating programmed cell death, especially the family of
B-cell lymphoma 2 (Bcl-2) proteins and various mitochondrial
factors, are intensively studied because of the known biochemical
effects of the long-term administration of antidepressants and
mood stabilizers, with regard to the supposed role of the survival,
plasticity and metabolism of neurons during mental and neurode-
generative diseases (Jope and Roh, 2006). Recently, it has been pro-
posed that antidepressants may exert their long-term therapeutic
effects by triggering cellular mechanisms that promote neuronal
plasticity (Manji et al., 2003) and neuroprotective pathways by
increasing the neurogenesis in the hippocampus (Malberg et al.,
2000).
Most cellular energy is obtained through oxidative phosphory-
lation, a process requiring the action of various respiratory enzyme
complexes located in a special structure of the inner mitochondrial
membrane, the mitochondrial respiratory chain. It is well de-
scribed that mitochondrial dysfunction has been implicated in
the pathogenesis of a number of diseases affecting the brain, such
as dementia, cerebral ischemia, Alzheimer’s disease and Parkin-
son’s disease (Blass, 2001; Brennan et al., 1985; Heales et al.,
1999; Schurr, 2002; Monsalve et al., 2007). Several recent works
also support the hypothesis that metabolism impairment is in-
volved in the pathophysiology of depression (Tretter et al., 2007;
Petrosillo et al., 2008; Kanarik et al., 2008; Stanyer et al.,
2008).The enzyme creatine kinase (CK), catalyses the reversible
transphosphorylation of creatine by adenosine triphosphate and
plays a key role in energy buffering and energy transport, particu-
larly in cells with high and ﬂuctuating energy requirements,
including neurons (Andres et al., 2008). It is also known that a dim-
inution of CK activity may potentially impair energy homeostasis,
contributing to cell death (Aksenov et al., 2000; David et al.,
1998) In addition, citrate synthase has been used as a quantitative
enzyme marker for the presence of intact mitochondria (Marco
et al., 1974), which may be related with mood disorders (Agostinho
et al., 2009).
Therefore, considering that neutrophins, energy metabolism
and cell signaling cascades are all involved in the pathophysiology
of mood disorders and that there are still no studies showing the
consistent effects of lamotrigine on these targets, the present study
was aimed to investigate the behavioral and physiological effects
of acute and chronic administration of lamotrigine in rats. The
behavioral effects were evaluated in the open ﬁeld and forced
swimming tests. Additionally, creatine kinase citrate, synthase
activities and mitochondrial respiratory chain (I, II, II–III and IV)
activities; Bcl-2, AKT and Gsk-3 expression; and BDNF and NGF
protein levels were assessed in the prefrontal cortex, hippocampus
and amygdala.2. Material and methods
2.1. Animals
Male Adult Wistar rats (60 days old) were obtained from the
breeding colony at UNESC (Universidade do Extremo Sul Catarin-
ense, Criciúma, SC, Brazil). They were housed ﬁve per cage with
food and water available ad libitum and were maintained on a
12-h light/dark cycle (lights on at 7:00 a.m.). All experimental pro-
cedures involving animals were performed in accordance with the
NIH Guide for the Care and Usage of Laboratory Animals and under
the Brazilian Society for Neuroscience and Behavior (SBNeC) rec-
ommendations for animal care, and with approval by the local
Ethics Committee under protocol number 01/2011.
2.2. Drugs and treatments
Lamotrigine was purchased from Sigma (Brazil) and imipra-
mine, a classic antidepressant was purchased from Novartis Phar-
maceutical Industry (São Paulo, Brazil). Different groups of rats
(n = 15 each) were administered intraperitoneally (i.p.) with saline
(control group), different doses of lamotrigine (10 mg/kg and
20 mg/kg) or imipramine (30 mg/kg) (positive control) in one sin-
gle dose (acute treatment) or over the course of 14 days, once a day
(chronic treatment), the protocols being in accordance with previ-
ous study executed by Kaster et al. (2007). All treatments were
administered in a volume of 1 ml/kg. The behavior tests (open-ﬁeld
and forced swimming tests) were evaluated one hour after the
administration of the last injection.
2.3. Open-ﬁeld test
This apparatus consists of a 45  60 cm brown plywood arena
surrounded by 50 cm high wooden walls and containing a frontal
glass wall. The ﬂoor of the open ﬁeld was divided into nine rectan-
gles (15  20 cm each) by black lines. Animals were gently placed
on the left rear quadrant and left to explore the arena. In a separate
series of experiments, rats were acutely treated with lamotrigine
(10 and 20 mg/kg), imipramine (30 mg/kg) and saline 60 min be-
fore exposure to the open-ﬁeld apparatus and after 12 days of
chronic treatment, rats were exposed to the open-ﬁeld apparatus.
The numbers of horizontal (crossings) and vertical (rearings) activ-
ities performed by each rat during the 5 min observation period
were counted by an expert observer, in order to assess the possible
effects of drug treatment on spontaneous locomotor activity.
2.4. Forced swimming test
The forced swimming test was conducted according to previous
reports (Garcia et al., 2008a,b; Porsolt et al., 1977; Detke et al.,
1995). The test involves two individual exposures to a cylindrical
tank ﬁlled with water, in which the rats cannot touch the bottom
of the tank or escape. The tank is made of transparent Plexiglas,
80 cm tall, 30 cm in diameter, and ﬁlled with water (22–23 C) to
a depth of 40 cm. For the ﬁrst exposure, rats without drug treat-
ment were placed in the water for 15 min (pre-test session).
Twenty-four hours later, rats were once again placed in the water
for a 5 min session (test session), and the immobility time of rats
were recorded in seconds. Rats were treated with lamotrigine,
imipramine or saline only 60 min before the second exposure to
the cylindrical tank of water (test session). On day 13 of chronic
treatment, 1 h after drug administration, the rats were individually
placed in the cylinder containing water for 15 min (pre-test ses-
sion). On the 14th day the rats received the last intraperitoneal
drug treatment, and after 1 h they were again subjected to the
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test session immobility time was recorded. After the behavioral
tests, in both acute and chronic treatments, all rats were killed
by decapitation and the skulls were immediately removed. The
prefrontal cortex, hippocampus and amygdala were quickly iso-
lated by hand dissection using a magnifying glass and a thin brush,
the dissection being based on histological distinctions described by
Paxinos and Watson (1986).
2.5. Neurotrophins measurement
The BDNF and NGF levels in the prefrontal cortex, hippocampus
and amygdala (n = 6–8 each) were measured by sandwich-ELISA,
according to the manufacturer’s instructions (Chemicon, USA for
BDNF and Millipore, USA & Canada for NGF). Brieﬂy, the rat pre-
frontal cortex, hippocampus and amygdala were homogenized in
phosphate buffer solution (PBS) with protease inhibitor cocktail
(Sigma). Microtiter plates (96-well ﬂat-bottom) were coated for
24 h with the samples diluted 1:2 in sample diluent and the stan-
dard curve ranged from 7.8 to 500 pg/ml of BNDF and NGF. The
plates were then washed four times with sample diluent and a
monoclonal anti-BNDF, and an anti-NGF rabbit antibody (diluted
1:1000 in sample diluent) was added to each well and incubated
for 3 h at room temperature. After washing, a peroxidase conju-
gated anti-rabbit antibody (diluted 1:1000) was added to each well
and incubated at room temperature for 1 h. After the addition of
the streptavidin-enzyme, substrate and stop solutions, the amount
of each neurotrophin was determined by absorbance in 450 nm.
The standard curve demonstrates a direct relationship between
Optical Density (OD) and the concentration. Total protein was
measured by Lowry’s method using bovine serum albumin as a
standard, as previously described by Lowry et al. (1951).
2.6. Respiratory chain enzyme activities
The homogenates (n = 5 each) were centrifuged at 800g for
10 min and the supernatants kept at 70 C until used for enzyme
activity determination. The maximal period between homogenate
preparation and enzyme analysis was always less than 5 days. Pro-
tein content was determined by the method described by Lowry
et al. (1951) using bovine serum albumin as standard. NADH dehy-
drogenase (complex I) was evaluated by the method described by
Cassina and Radi (1996) by the rate of NADH-dependent ferricya-
nide reduction at 420 nm. The activity of succinate: Cytochrome c
oxidoreductase (complexes II and II–III) were determined according
to the method of Fischer et al, measured by Cytochrome c reduction
from succinate. The activity of Cytochrome c oxidase (complex IV)
was assayed according to themethoddescribed byRustin et al,mea-
sured by following the decrease in absorbance due to the oxidation
of previously reduced Cytochrome c at 550 nm with 580 nm as ref-
erence wavelength (e = 19.1 mM1cm1). The reaction buffer con-
tained 10 mM potassium phosphate, pH 7.0, 0.6 mM n-dodecyl-D-
maltoside, 2–4 lg1 homogenate protein and the reaction was initi-
ated with addition of 0.7 lg1 reduced cytochrome c. The activity of
complex IV was measured at 25 C for 10 min. The activities of the
mitochondrial respiratory chain complexes were described as
nmolmin1mgprotein1.
2.7. Creatine kinase activity
The homogenates (n = 5 each) were centrifuged at 800g for
10 min. and the supernatants kept at 70 C until used for creatine
kinase activity determination. The maximal period between
homogenate preparation and enzyme analysis was always less
than 5 days. Protein content was determined by the method
described by Lowry et al. (1951) using bovine serum albumin asstandard. Creatine kinase activity was measured in brain homoge-
nates pre-treated with 0.625 mM lauryl maltoside. The reaction
mixture consisted of 60 mM Tris–HCl, pH 7.5, containing 7 mM
phosphocreatine, 9 mM MgSO4 and approximately 0.4–1.2 lg pro-
tein in a ﬁnal volume of 100 lL. After 15 min of preincubation at
37 C, the reaction was started by the addition of 0.3 lmol of
ADP plus 0.08 lmol of reduced glutathione. The reaction was
stopped after 10 min by the addition of 1 lmol of hydroxymercu-
ribenzoic acid. The creatine formed was estimated according to
the colorimetric method of Hughes (1962). The color was devel-
oped by the addition of 100 lL 2% a-naphthol and 100 lL 0.05%
diacetyl in a ﬁnal volume of 1 mL and read spectrophotometrically
after 20 min at 540 nm. Results were described as
nmolmin1mgprotein1.
2.8. Citrate synthase activity
The prefrontal cortex, hippocampus and amygdala (n = 5 each)
were homogenized (1:10, w/v) in SETH buffer (0.25 M sucrose,
1 mM EDTA, 10 mM Tris–HCl, pH 7.4). The homogenates were cen-
trifuged at 800g for 10 min and the supernatants were kept at
70 C until it will be used for enzyme activity determination. Pro-
tein content was determined by the method described by Lowry
et al. (1951) using bovine serum albumin as standard. Citrate syn-
thase activity was assayed according to the method described by
Shepherd and Garland (1969). The reaction mixture contained
100 mM Tris, pH 8.0, 100 mM acetyl CoA, 100 mM 5,5-di-thiobis
(2-nitrobenzoic acid), 0.1% triton X-100, and 2–4 g supernatant
protein and was initiated with 100 Moxaloacetate and monitored
at 412 nm for 3 min at 25 C (the ﬁnal volume of reaction mixture
was 0.3 mL).
2.9. Protein analysis by immunoblotting
The Prefrontal cortex, hippocampus and amygdala tissues (n = 5
each) were excised. The tissues were homogenized immediately in
extraction buffer (mM) (1% Triton-X 100, 100 Tris, pH 7.4, contain-
ing 100 sodium pyrophosphate, 100 sodium ﬂuoride, 10 EDTA, 10
sodium vanadate, 2 PMSF and 0.1 mg of aprotinin/ml) at 4 C with
a Polytron PTA 20S generator (Brinkmann Instruments model PT
10/35) operated at maximum speed for 30 s. The extracts were
centrifuged at 11,000 rpm and 4 C in a Beckman 70.1 Ti rotor (Palo
Alto, CA) for 40 min to remove insoluble material, and the superna-
tants of these tissues were used for protein quantiﬁcation, using
the Bradford method. Proteins were denatured by boiling in
(Laemmli, 1970) sample buffer containing 100 mM DTT (De Souza
et al., 2003). After this, 0.2 mg of protein extracts obtained from
each tissue were separated by SDS–PAGE, transferred to nitrocellu-
lose membranes and blotted with anti-AKT, anti-Bcl-2 and anti-
GSK-3b. Antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Chemiluminescent detection was performed with
horseradish peroxidase-conjugate secondary antibodies. Visualiza-
tion of the protein bands was performed by exposure of the mem-
branes to RX-ﬁlms. The original membrane was stripped and
reblotted with actin loading protein (bands not showing). After
transfer, the membrane was stained with Ponceau and bands were
visualized, photographed and quantiﬁed before the primary anti-
body, to control the transfer. Band intensities were quantitated
by optical densitometry (Scion Image software, ScionCorp, Freder-
ick, MD) of the developed autoradiographs.
2.10. Statistical analysis
All data are presented as mean ± SEM. Differences among exper-
imental groups in the forced swimming and open ﬁeld tests and in
the assessment of the biochemical analysis were determined by
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was signiﬁcant; P values <0.05 were considered to be statistically
signiﬁcant.
3. Results
The effects of the acute and chronic administration of lamotri-
gine on the immobility times are illustrated in Fig. 1A. In the acute
(F(3–21) = 6.148; p = 0.04 Fig. 1A) and chronic (F(3–66) = 6.222;
p = 0.01 Fig. 1A) treatments we observed a decrease in the immo-
bility time with imipramine at the dose of 30 mg/kg and lamotri-
gine at the doses of 10 and 20 mg/kg, compared with saline.
Interestingly, in the open-ﬁeld test both acute and chronic
treatments with imipramine or lamotrigine did not modify the
number of crossings (acute; F(3–55) = 0.595; p = 0.62; Fig. 1B;
chronic; F(3–53) = 3.411; p = 0.24 Fig. 1B) and rearings (acute;
F(3–55) = 0.393; p = 0.75; chronic; F(3–53) = 0.844; p = 0.47 Fig. 1B),
compared with saline.
With regards to the acute treatment, there was an increase the
BDNF levels in the prefrontal cortex with lamotrigine at the dose
of 20 mg/kg (F(3–16) = 5.501; p = 0,009 Fig. 2A), compared with sal-
ine, but BDNF protein levels did not alter in the prefrontal cortex
with imipramine at the dose of 30 mg/kg (F(3–16) = 5.501; p = 0.22
Fig. 2A) and with lamotrigine at the dose of 10 mg/kg
(F(3–16) = 5.501; p = 0.91 Fig. 2A), compared with saline. The
amygdala (F(3–16) = 1.292; p = 0,31 Fig. 2A) and the hippocampus
(F(3–16) = 2.844; p = 0.71 Fig. 2A) did not have any alterations in their
BDNF levels after acute treatment. In the chronic treatment data, we
found an increase occurred in the BDNF levels in the prefrontal cor-
tex with lamotrigine at the dose of 10 and 20 mg/kg (F(3–16) = 8.478;
p = 0.01 Fig. 2A), compared with saline, but BDNF protein levels did
not alter in the prefrontal cortex with imipramine (F(3–16) = 8.478;*
*
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Fig. 1. The effects of administration of acute and chronic doses of lamotrigine and imipra
on the number of crossings and rearings (B) of rats subjected to the open ﬁeld test. Bars
ANOVA followed by Tukey post-hoc test.p = 0.62 Fig. 2A), compared with saline. In the amygdala (F(3–16) =
2.676; p = 0.82; Fig. 3B) and in the hippocampus (F(3–16) = 1.693;
p = 0.20; Fig. 2A), there were no alterations in the BDNF levels after
chronic treatment.
The acute treatment did not alter the NGF protein levels in the
prefrontal cortex (F(3–16) = 1.024; p = 0.40 Fig. 2B), in the amyg-
dala (F(3–16) = 3.076; p = 0.58 Fig. 2B) or in the hippocampus
(F(3–16) = 0.095; p = 0.96 Fig. 2B). The chronic treatment increased
the NGF levels in the prefrontal cortex with lamotrigine at the
dose of 10 and 20 mg/kg (F(3–15) = 8.982; p = 0.01 Fig. 2B), com-
pared with saline, but the NGF protein levels did not alter in the
prefrontal cortex with imipramine at the dose of 30 mg/kg
(F(3–15) = 8.982; p = 0.57 Fig. 2B). The amygdala (F(3–16) = 0,230;
p = 0.87 Fig. 2B) and the hippocampus (F(3–16) = 3.2080; p = 0.51
Fig. 2B) did not have alterations in the BDNF levels after chronic
treatment.
The acute treatment increased the citrate synthase activity in
the amygdala with imipramine at the dose of 30 mg/kg
(F(3–10) = 6.474; p = 0.02 Fig. 3A) compared with saline. In the pre-
frontal cortex and hippocampus there were no alterations in the
citrate synthase activity after acute treatment. The chronic treat-
ment did not alter the citrate synthase activity in the prefrontal
cortex (F(3–11) = 0.460; p = 0.71 Fig. 3A), amygdala (F(3–12) = 2.676;
p = 0.94 Fig. 3A) or hippocampus (F(3–12) = 3.079; p = 0.68
Fig. 3A).
The acute treatment increased the creatine kinase activity in the
amygdala with imipramine at the dose of 30 mg/kg (F(3–15) = 5.415;
p = 0.01 Fig. 3B), compared with saline. The chronic treatment in-
creased the creatine kinase activity in the hippocampus with imip-
ramine at the dose of 30 mg/kg and lamotrigine at the dose of
10 mg/kg (F(3–15) = 7.967; p = 0.02 Fig. 3B), compared with control
group.* *
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Fig. 2. The effects of administration of acute and chronic does of lamotrigine and imipramine on the BDNF protein levels (A) and NGF protein levels (B) in the prefrontal
cortex, hippocampus and amygdala. Bars represent means ± S.E.M. (n = 6–8). ⁄P < 0.05 compared to saline group according to ANOVA followed by Tukey post-hoc test.
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activity in the prefrontal cortex with imipramine at the dose of
30 mg/kg and lamotrigine at the dose of 10 mg/kg (F(3–14) =
10.859; p < 0.001 Fig. 4A) comparedwith control group. The chronic
treatment did not alter the mitochondrial complex I activity in the
prefrontal cortex (F(3–14) = 0.570; p = 0.64 Fig. 4A), amygdala
(F(3–14) = 2.599; p = 0.09 Fig. 4A) or hippocampus (F(3–12) = 0.875;
p = 0.48 Fig. 4A). The acute administration increased the mitochon-
drial complex II activity in the amygdala with imipramine at the
dose of 30 mg/kg and lamotrigine at the dose of 20 mg/kg
(F(3–13) = 21.798; p < 0.001 Fig. 4B), and in the hippocampus with
lamotrigine at the dose of 10 mg/kg (F(3–11) = 5.643; p = 0,02
Fig. 4B) compared with saline. The chronic treatment increased
the mitochondrial complex II activity in the prefrontal cortex
(F(3–15) = 19.218; p < 0,001 Fig. 4B) and hippocampus (F(3–12) =
4.471; p = 0,03 Fig. 4B) with imipramine at the dose of 30 mg/kg,
compared with saline. The acute administration did not alter the
mitochondrial complex II–III activity in the prefrontal cortex
(F(3–16) = 0,759; p = 0,53 Fig. 4C), amygdala (F(3–16) = 2.451;
p = 0.10 Fig. 4C) and hippocampus (F(3–16) = 1.519; p = 0,24
Fig. 4C). The chronic treatment increased the mitochondrial com-
plex II-III activity in the prefrontal cortex (F(3–15) = 4.175; p = 0,03
Fig. 4C) and hippocampus (F(3–13) = 10.168; p = 0.001 Fig. 4C) withimipramine at the dose of 30 mg/kg and in the amygdala
(F(3–14) = 10.512; p = 0.001 Fig. 4C) with all treatments, but did not
alter in the prefrontal cortex (F(3–15) = 4.175; p > 0.05 Fig. 4C)
and in the hippocampus (F(3–13) = 10.168; p > 0.05 Fig. 4C). The
acute administration increased the mitochondrial complex IV
activity in the hippocampus (F(3–13) = 18.471; p < 0,001 Fig. 4D)
with all treatments, compared with saline, but did not alter in the
prefrontal cortex (F(3–12) = 0.828; p = 0.50 Fig. 4D) and amygdala
(F(3–11) = 4,514; p = 0,27 Fig. 4D). The chronic treatment did
not alter the mitochondrial complex IV activity in the prefrontal
cortex (F(3–13) = 0.689; p = 0.57 Fig. 4D), amygdala (F(3–16) =
3.666; p = 0.35 Fig. 4D) or hippocampus (F(3–11) = 2.317; p = 0.13
Fig. 4D).
The acute treatment decreased the Bcl-2 protein levels in the
prefrontal cortex (F(3–12) = 106.818; p < 0,001 Fig. 5A) and in the hip-
pocampus (F(3–12) = 265,226; p < 0,001 Fig. 5A) with imipramine at
the dose of 30 mg/kg and lamotrigine at the dose of 20 mg/kg, and
also in the amygdala (F(3–12) = 87.304; p < 0.001 Fig. 5A) with all
treatments, comparedwith saline. The chronic treatment decreased
the Bcl-2 protein levels in the prefrontal cortex (F(3–12) = 310.093;
p < 0.001 Fig. 5A), amygdala (F(3–12) = 238.818; p < 0.001 Fig. 5A)
and hippocampus (F(3–12) = 557.669; p < 0.001 Fig. 5A) with all
treatments.
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1168 H.M. Abelaira et al. / Neurochemistry International 59 (2011) 1163–1174The acute treatment increased the AKT protein levels in the pre-
frontal cortex (F(3–12) = 49.088; p = 0.000 Fig. 5B)with imipramine at
the dose of 30 mg/kg, in the amygdala (F(3–12) = 70.335; p < 0.001
Fig. 5B) with lamotrigine at the dose of 20 mg/kg and in the hippo-
campus (F(3–12) = 21.011; p = 0.009 Fig. 5B), with imipramine at the
dose of 30 mg/kg and with lamotrigine at the dose of 20 mg/kg,
compared with saline. The acute treatment also decreased the AKT
protein levels in the amygdala with imipramine at the dose of
30 mg/kg (F(3–12) = 70.335; p = 0.04 Fig. 5B) and in the hippocampus
with lamotrigine at the dose of 10 mg/kg (F(3–12) = 21.011; p = 0.04
Fig. 5B). The chronic treatment increased the AKT protein levels in
the prefrontal cortex (F(3–12) = 121.938; p < 0,001 Fig. 5B),
amygdala (F(3–12) = 83.853; p < 0.001 Fig. 5A) and hippocampus
(F(3–12) = 58.262; p < 0,001 Fig. 5B) after all treatments.
The acute treatment decreased the GSK-3 protein levels in the
prefrontal cortex with imipramine at the dose of 30 mg/kg and
lamotrigine at the dose of 20 mg/kg (F(3–12) = 126.185; p < 0.001
Fig. 5C), compared with saline. In the amygdala (F(3–12) =
328.079; p < 0.001 Fig. 5C) the GSK-3 protein levels decreased with
all doses, and in the hippocampus with imipramine at the dose of
30 mg/kg (F(3–12) = 80.214; p < 0.001 Fig. 5C) after acute treatment,
compared with saline. The chronic treatment decreased the GSK-3
protein levels in the prefrontal cortex (F(3–12) = 168.217; p = 0.001
Fig. 5C) and in the amygdala (F(3–12) = 535.095; p < 0.001 Fig. 5C)
with all doses, and in the hippocampus (F(3–12) = 596.903;
p < 0.001 Fig. 5C) with imipramine at the dose of 30 mg/kg and
lamotrigine at the dose of 20 mg/kg.4. Discussion
Depression is a clinically and biologically heterogeneous dis-
ease, with 10–30% of women and 7–15% of men likely to suffer
from depression in their life-time (Briley and Moret, 2000). How-
ever, combinations of multiple genetic factors may be involved in
the development of depression, because a defect in a single gene
usually fails to induce the expression of multifaceted symptoms
of depression (Larsen et al., 2010). Also, various non-genetic factors
such as stress, affective trauma, viral infection, and neurodevelop-
mental abnormalities increase the complexity of the pathogenesis
of the disease. Thus, extensive studies have led to a variety of
hypotheses for the molecular mechanism of depression, but a def-
inite pathogenic mechanism has yet to be deﬁned.
The behavioral effects induced by imipramine in rats reported
in the present study are in agreement with literature data, which
support an antidepressant action for imipramine in basic and clin-
ical studies. In fact, ﬁndings from our group have demonstrated
that a single injection of imipramine (10 and 20 mg/kg) and
chronic administration of imipramine (10, 20 and 30 mg/kg) de-
creased the immobility time of rats in the forced swimming test,
without modifying the locomotor activity (Garcia et al., 2008a,b).
Our results showed that acute and chronic treatment with lamotri-
gine decreased the immobility time of rats in the forced swimming
test, without changing locomotor activity in open ﬁeld test
compared to saline. Consistent with our study, Consoni et al.
(2006) showed that lamotrigine (10 mg/kg) decreased immobility
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addition, lamotrigine neither changed locomotion in the open-ﬁeld
test nor impaired habituation. Kaster et al. (2007) also showed that
lamotrigine (20–30 mg/kg) decreased the immobility time in the
forced swimming test. Still, Mikulecká et al. (2004) showed that
administration of lamotrigine (10 and/or 20 mg/kg for 6 consecu-
tive days) did not change motor abilities and behavior in an open
ﬁeld. However, recently Barbee et al. (2011) in a double-blind pla-
cebo-controlled evaluating patients with treatment-resistent
depression showed that there was no difference between lamotri-
gine and placebo groups. The authors suggesting that lamotrigine’s
efﬁcacy might focus on speciﬁc subgroups with depression.
The precise molecular mechanisms responsible for the antide-
pressant action of lamotrigine are still not fully understood. Indeed
studies have suggested that Antiepileptic drugs, such as lamotri-
gine presents targets of action in the synapse, which could be rel-
evant in epilepsy and other disorders. The mechanisms of action
including, modulating ion channels and receptors and intracellular
signaling pathways (Johannessen, 2008; Mazza et al., 2007). Inter-
estingly, evidence suggests that a variety of intracellular pathways
and signal transduction cascades are involved in both the patho-
physiology and treatment of depression (Coyle and Duman,
2003; Duman, 1998; Duman et al., 1997; Vaidya et al., 2007). Many
antidepressant drugs acutely increase monoamine levels, but the
requirement for chronic treatment has led to the hypothesis that
long-term adaptations are necessary for the therapeutic actions
of these treatments (Duman et al., 1994). Among the many long
term targets of antidepressant treatments may be the regulation
of neurotrophins, such as brain-derived neurotrophic factor (BDNF)
and nerve growth factor (NGF).
Our results showed that the acute and chronic treatments with
lamotrigine increased the BDNF levels in the prefrontal cortex.
Consistent with this result, Li et al. (2010) showed that the chronic
treatment with lamotrigine (30 mg/kg) increased BDNF protein
expression in the prefrontal cortex, but contrarily to our result
the BDNF protein expression was also increased in the hippocam-
pus. We cannot explain why such discrepancies occur, but they
may be related to the dosage used. In addition, a study by our
group showed that acute administration of ketamine at the higher
dose 15 mg/kg, but not in lower doses, increased BDNF protein lev-
els in the rat hippocampus. Our results also showed that chronic,
but not acute; treatment with lamotrigine increased the NGF levels
in the prefrontal cortex. Another result showed that in rats, treat-
ment with lithium at various dosages increased NGF in the hippo-
campus, amygdala, frontal cortex, and limbic forebrain, whereas
NGF in the striatum, midbrain, and hypothalamus was unchanged
(Hellweg et al., 2002). Our results showed that imipramine did not
alter de BDNF and NGF levels, suggesting that the antidepressant
effects of lamotrigine may be related, at least in part, by its action
on the neurotrophins, which was not observed with the classic
antidepressant.
It is important that others studies have been shown effects of
imipramine on the BDNF. In fact, chronic treatment with imipra-
mine increased BDNF mRNA levels in the dentate gyrus of the dor-
sal hippocampus (Larsen et al., 2010). Réus et al. (2011) also
pointed to increase on the BDNF levels with imipramine in the pre-
frontal cortex, hippocampus and amygdala by imunoblot, its
effects were more pronounced when co-administrated with keta-
mine, an antagonist of NMDA receptor. In contrast, others no have
been shown effects of imipramine on the BDNF levels in the hippo-
campus (Garcia et al., 2008a,b; Fortunato et al., 2010), suggesting
that imipramine presents effects on the BDNF related with brain
area and technical used.
There is a strong body of evidence suggesting that dysfunction in
brain metabolism is related to neuropsychiatry disorders, such as,
depression and bipolar disorder (Albert et al., 2002; Kato and Kato,2000; Konradi et al., 2004). Our ﬁndings showed that imipramine
increased the citrate synthase activity in the amygdala after acute
treatment, but not in the chronic treatment. In fact, a previous study
already showed that the acute administration (but not chronic),
with antipsychotic olanzapine and antidepressant ﬂuoxetine in-
creased citrate synthase activity in the brain areas
(Agostinho et al., 2009), suggesting that the results could be related
to desensitization to the effects of the repeated administration of
drugs, or to an adaptation mechanism.
Considering that metabolism impairment is probably involved
in the pathophysiology of depressive disorders, an increase in cre-
atine kinase activity by antidepressants may be an important
mechanism of action of these drugs. In the present work we
showed that CK was increased in the amygdala after the adminis-
tration of imipramine in the acute treatment and in the hippocam-
pus after the administration of imipramine and lamotrigine in the
chronic treatment. Another study showed that CK activity was in-
creased after the chronic administration of paroxetine (Santos
et al., 2009). Assis et al. (2009) also reported that the acute admin-
istration of ketamine and imipramine increased creatine kinase
activity in the rat brain. On the other hand, the chronic administra-
tion of nortriptiline and venlafaxine did not affect CK activity in the
rat brain (Santos et al., 2009). Some other studies also point to the
possibility that drugs used in the treatment of such disorders mod-
ulate energy metabolism (Búrigo et al., 2006; Gamaro et al., 2003;
Streck et al., 2006). Studies have reported brain energy metabolism
impairment in an animal model of mania induced by amphet-
amine. It has been demonstrated that the administration of
amphetamine inhibited citrate synthase (Corrêa et al., 2007) and
creatine kinase (Streck et al., 2008) activity in the brain of rats.
Thus, it is possible that diminution of brain energy metabolism is
involved in the pathophysiology of psychiatric disorders (Fattal
et al., 2006; Madrigal et al., 2001).
In this context, Gardner et al. (2003) showed a signiﬁcant de-
crease of mitochondrial ATP production rates and mitochondrial
enzyme ratios in muscle in major depressive disorder patients,
when compared to controls. In the present study we demonstrated
that both acute and chronic treatments with imipramine or lamo-
trigine altered respiratory chain complexes in rat brain, however
these alterations were different with relation to protocols (acute
or chronic), complex and brain area.
Furthermore, study from our group also showed that mitochon-
drial respiratory chain complexes I, III and IV were inhibited after
chronic mild stress in the cerebral cortex and cerebellum, and
acute administration of ketamine reversed this inhibition (Rezin
et al., 2009). Madrigal et al. (2001) also reported that complexes
I–III and II–III of mitochondrial respiratory chain were inhibited
in rat brain after chronic stress (immobilization for six hours over
21 days). Additionally, Ben-Shachar and Karry (2008) demon-
strated reductions in mRNA and protein of complex I subunits
NDUFV1, NDUFV2 and NADUFS1 in the postmortem cerebellum
from patients with depression. Hroudova and Fisar (2010) using
an in vitro study from pig brain, demonstrated that the complex
I, II and IV activity decreased with antidepressants and mood
stabilizers, suggesting in this study that antidepressants generally
act as inhibitors of electron transport chain. Our ﬁndings also
showed an inhibitory effect on the activity of complex I, but
contrarily to this, lamotrigine and imipramine increased the activ-
ities of complexes II, II-III and IV, suggesting that the increase in
the complexes II, II-III and IV activity may be related, at least in
part to compensating the decrease of complex I activity. Such,
the effects of lamotrigine and imipramine on the mitochondrial
respiratory chain could be positive, taking into account that there
is impairment in energy metabolism related to depression
(Ben-Shachar and Karry, 2008; Rezin et al., 2009; Madrigal et al.,
2001).
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maintained to ensure the health of every human being. Recent
ﬁndings indicate that approximately one-half of all major human
diseases are a consequence of abnormal apoptosis (Reed, 2002).
Neurodegeneration mediated by apoptosis can be initiated by
Bax translocation from the cytosol to the mitochondria, where it
affects membrane permeability and permits cytochrome c release
and subsequent activation of caspases (Yang et al., 1995; Ghribi
et al., 2001). Inappropriate apoptosis can cause autoimmune and
neurodegenerative disorders, as well as heart disease, while resis-
tance to apoptosis can promote cancer and impede the effective-
ness of cancer therapeutics. Our results demonstrate that
imipramine and lamotrigine decreased the Bcl-2 expression in
the prefrontal cortex, amygdala and hippocampus in the acute
and chronic treatments. Peng et al. (2008) showed that 3 lM imip-
ramine treatment signiﬁcantly up-regulated the mRNA and protein
expression and Bcl-2 in day-7 imipramine-treated neural stem
cells (NSCs). Huang et al. (2007) also showed that desipramine in-
creased the Bcl-2 expression in day 3 DP-treated NSCs. Another
study demonstrated that by the fourteenth day, (but not acute
treatment with citalopram), imipramine and amitriptyline in mice
had signiﬁcantly elevated the hippocampal Bcl-2 protein expres-
sion as compared to vehicle treated animals. (Murray and Hutson,
2007), suggested that their elevation reﬂects a compensatory
mechanism. Consistent with our results, another study showed a
signiﬁcant decrease of antiapoptotic Bcl-2 protein upon ﬂuoxetine
treatment, which is a known molecular event in the initiation of
apoptosis, suggesting that the effects of ﬂuoxetine over antiapo-
ptotic Bcl-2 may be interpreted as activation of apoptotic response.
GSK-3 (isoform b) is an important regulator of glycogen synthe-
sis, gene transcription, synaptic plasticity, apoptosis (cell death),
cellular structure and resilience. It has been suggested that GSK-
3 regulates behavior by affecting b-catenin, glutamate receptors,
circadian rhythms, and serotonergic neurotransmission (Beaulieu
et al., 2008). All of these have been implicated in the pathophysiol-
ogy of severe mood disorders. Our results showed a decreased in
the prefrontal cortex, amygdala and hippocampus with imipra-
mine and lamotrigine in the acute and chronic treatments. Another
study showed that lithium induces neurotrophic and neuroprotec-
tive effects in rodents, partly due to GSK-3b inhibition (Gould and
Manji, 2005). Li et al. (2004) also showed that treatment with
monoamine reuptake inhibitors ﬂuoxetine and imipramine also in-
creased the level of Gsk-3. Valproate was initially reported to inhi-
bit GSK-3b activity in SH-SY5Y cells (Chen et al., 1999; Chuang,
2005), but these effects have not been conﬁrmed in neuronal cells
(Gurvich and Klein, 2002). In general, increased activity of GSK-3 is
proapoptotic, whereas inhibiting GSK-3 prevents apoptosis. Thus,
we suggest that in our study the effects of lamotrigine and imipra-
mine were antiapototic, since both inhibited GSK-3.
Accumulating evidence suggests that impaired AKT and/or ERK
signaling contributes to the pathogenesis of schizophrenia, bipolar
disorder andmajor depressionandpharmacological studies indicate
that antipsychotics activate these signaling pathways in vivo or
in vitro (Arguello and Gogos, 2008; Beaulieu et al., 2006; Lu et al.,
2004; Zhang et al., 2005). Previous reports have demonstrated that
AKT is not only involved in cell growthbut is also involved in glucose
metabolism/uptake (Hajduch et al., 2001; Lawlor and Alessi, 2001).
AKT was shown to be a keymediator of the signal transduction pro-
cess andmediates many of the survival signals (Brunet et al., 2001).
The present study showed an increase in the prefrontal cortex with
imipramineand in theamygdala andhippocampuswith lamotrigine
in the acute treatments. On the other hand, our data also showedde-
creases in the amygdala with imipramine, and in the hippocampus
with lamotrigine in the acute treatment. This effect couldbe alterna-
tively explained by its capacity to upregulate gene expression
through inhibiting histone-deacetylase, as has been reported (Har-wood and Agam 2003; De Sarno et al., 2002). Aubry et al. (2009)
showed that lithium, valproate, olanzapine and clozapine enhance
proliferation and protect cells against serum withdrawal-induced
injury. These drugs also activated AKT-1 and GSK-3b phosphoryla-
tion (Aubry et al., 2009). Interestingly, gene expression of AKT-1
mRNA and protein, but not GSK-3b, was increased. Another study
showed that sertraline potently inhibited the phosphorylation of
AKT and caused cell death. (Reed, 2002). Lamotrigine has a potent
activitydependenton ionchannels (i.e., Na+andCa+) andcouldhave
an indirect actionon signal transduction (Xie andHagan, 1998). Con-
sistent with our results, lamotrigine had an indirect action on AKT
protein levels. Whether lamotrigine has direct actions on these
intracellular signaling molecules has not been extensively studied
to date. To our knowledge, no other previous assay has tested such
a complex mechanism.
Reduced glutamatergic neurotransmission has been related to
the antidepressant effect of lamotrigine. In fact, electrophysiologi-
cal studies in the amygdala (Wang et al., 2002) and in the striatum
(Calabrese et al., 1999) showed that lamotrigine reduced excitatory
post-synaptic potential mediated by glutamate, an effect reversed
when exogenous glutamate was applied, ﬁndings consistent with
the proposal that lamotrigine had an inhibitory action on gluta-
mate release. Functional antagonists of the N-methyl-d-aspartate
(NMDA) complex exhibit an antidepressant- like effect in animal
models of depression. In adition, NMDA receptor antagonists have
demonstrated alter neutrophins (Réus et al., 2010), and energy
metabolism (Rezin et al., 2009; Assis et al., 2009) suggesting that
changes are mediated by glutamate action through NMDA recep-
tor, thus, the effects exerted by lamotrigine in these pathways,
may be related, at least in part to its action on the glutamatergic
system.5. Conclusions
In conclusion, this is the ﬁrst study that directly compares the
effects of acute and chronic lamotrigine treatment depressive-like
symptoms together with the effects on neurotrophins, metabolism
energy, signaling cascade. The behavioral effects of lamotrigine can
be attributed to its action on neurochemistry pathways related to
depression. However, the results ﬁndings in the present research
were in preclinical study and we suggest clinical studies evaluating
serum or postmortem brain from patients with major depression
and to evaluate whether lamotrigine could be a new option for this
impairment disorder.Acknowledgements
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